Discover the place where innovation drives performance.
Vision
Improving the quality of life of mankind
by developing treatments
for intractable and rare diseases
Goal
Becoming a global innovative pharmaceutical company
by launching blockbuster products
through Open Collaboration
R&D Portfolio
New Drugs
- Expansion of launching contury of Fexuclue and expansion of its pipeline
- Launching Envlo and expansion of its pipeline
- Strengthen the portfolio of autoimmune, fibrosis, metabolic and cancer treatments.
- New modality in drug discovery (TPD)
Biologics
- Development of stem cell therapy for intractable and rare diseases
- Expansion of Jeuveau (Nabota)’s indications
- EGF Line ext.Expansion of EGF pipeline
- Development of Bio-convergence medical devices
- Identification of age-related candidate
New Products
- Global expansion of Luphere Depot Injection in the U.S. and Japan
- Development of GLP-1-based depot injection for the treatment of obesity
- Development of differentiated extended-release, combination, and first-generation generics based on platform formulation technologies
- Development of proprietary medicines for global commercialization
C&D(Connect & Development)
- Focus on cell & gene therapy development through Open Collaboration
- Expansion of therapeutic areas such as anti-cancer / metabolism diseases / immuno-diseases / vaccine
R&D Objectives
Development of First-/Best-in-class drugs
- Development of new drugs that benefit patients
- Strengthening global leadership in developing autoimmune, fibrosis, metabolic and cancer treatments through open collaboration .
- Securing capacity to discover sustainable new drug assets
Development of next-generation Biologics
- Development of smart stem cell therapy
- Life cycle extension of Jeuveau(Nabota)
- Development of Cell & Gene Therapy
- Development of exosome
- Development of First/Best in class Biopharmaceuticals Expansion of new pipelines through Open collaborations
Innovative platform-based IMD development
- Development of long-acting injectable formulations
- Development of new drug delivery routes based on microneedle technology
- Expansion of Nasal Spray pipeline
- Expansion of OROS/Polycap oral drug delivery platform technologies
Expanding the scope of external R&D
- Exploring cutting-edge technologies
- Securing world leading therapy technologies through C&D
- Maximizing future values by optimal business model